Programming of cells for tolerogenic therapies

• US 9,381,235 B2
• Filed: 02/20/2014
• Issued: 07/05/2016
• Est. Priority Date: 07/31/2009
• Status: Active Grant

• Current Assignee: Forsyth Dental Infirmary For Children, President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: Forsyth Dental Infirmary For Children, President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Sands, Roger Warren, Barros e Silva, Eduardo Alexandre, Kawai, Toshihisa, Mooney, David J.
• Primary Examiner(s): Long, Scott
• Application Number:
  US14/185,494
• Publication Number:
  US 20140234423A1
• Time in Patent Office: 866 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/577 tolerising response
• CPC Class Codes: A61K 2039/70 Multivalent vaccine
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/102 Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
• CPC Class Codes: A61K 39/35 Allergens
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.

Claims

1. A method of reducing the severity of an autoimmune disorder, comprising identifying a subject suffering from an autoimmune disorder and administering to said subject a scaffold composition comprising an antigen, a recruitment composition, and a tolerogen,

wherein said antigen is derived from a cell to which a pathologic autoimmune response associated with said disorder is directed;

wherein said tolerogen induces immune tolerance or a reduction in an immune response;

wherein said tolerogen is selected from the group consisting of retinoic acid, rapamycin, aspirin, and vasoactive intestinal peptide; and

wherein the scaffold composition does not comprise IL-10, dexamethasone, vitamin D, or TGF-beta.

2. The method of claim 1, wherein said autoimmune disorder is type 1 diabetes.

3. The method of claim 1, wherein said antigen comprises a pancreatic cell antigen.

4. The method of claim 3, wherein said antigen comprises insulin, proinsulin, glutamic acid decarboxylase-65 (GAD65), insulinoma-associated protein 2, heat shock protein 60, ZnT8, or islet-specific glucose-6-phosphatase catalytic subunit.

5. The method of claim 1, wherein said autoimmune disorder is multiple sclerosis.

6. The method of claim 5, wherein said antigen comprises myelin basic protein, myelin proteolipid protein, myelin-associated oligodendrocyte basic protein, or myelin oligodendrocyte glycoprotein.

7. The method of claim 1, wherein said recruitment composition comprises GM-CSF, FMS-like tyrosine kinase 3 ligand, N-formyl peptides, fractalkine, or monocyte chemotactic protein-1.

8. The method of claim 7, wherein said recruitment composition comprises GM-CSF.

9. The method of claim 1, wherein said scaffold composition comprises a non-inflammatory polymer.

10. The method of claim 9, wherein said non-inflammatory polymer comprises alginate, poly(ethylene glycol), hyaluronic acid, collagen, gelatin, poly(vinyl alcohol), fibrin, poly(glutamic acid), peptide amphiphiles, silk, fibronectin, chitin, poly(methyl methacrylate), poly(ethylene terephthalate), poly(dimethylsiloxane), poly(tetrafluoroethylene), polyethylene, polyurethane, poly(glycolic acid), poly(lactic acid), poly(caprolactone), poly(lactide-co-glycolide) (PLGA), polydioxanone, polyglyconate, BAK;

poly(ortho ester I), poly(ortho ester) II, poly(ortho ester) III, poly(ortho ester) IV, polypropylene fumarate, poly[(carboxy phenoxy)propane-sebacic acid], poly[pyromellitylimidoalanine-co-1,6-bis(p-carboxy phenoxy)hexane], polyphosphazene, starch, cellulose, albumin, polyhydroxyalkanoates, poly(lactide), or poly(glycolide).

11. The method of claim 1, wherein said scaffold composition comprises a hydrogel.

12. The method of claim 11, wherein said hydrogel comprises an alginate gel polymer.

13. The method of claim 12, wherein said hydrogel comprises 1-5% alginate gel polymer.

14. The method of claim 13, wherein said alginate gel polymer is crosslinked.

15. The method of claim 1, wherein the tolerogen is encapsulated in poly(lactide-co-glycolide) (PLGA) microspheres.

16. The method of claim 1, wherein said scaffold composition is administered by injection, implantation, topically affixing a skin patch comprising the scaffold composition, or delivering the scaffold composition by aerosol into a lung or nasal passage of the subject.

17. The method of claim 16, wherein said scaffold composition is administered by intradermal implantation.

18. The method of claim 1, wherein said autoimmune disorder is Crohn'"'"'s disease, rheumatoid arthritis, Systemic lupus erythematosus, Scleroderma, Alopecia areata, Antiphospholipid antibody syndrome, Autoimmune hepatitis, Celiac disease, Graves'"'"' disease, Guillain-Barre syndrome, Hashimoto'"'"'s disease, Hemolytic anemia, Idiopathic thrombocytopenic purpura, inflammatory bowel disease, ulcerative colitis, inflammatory myopathies, Polymyositis, Myasthenia gravis, Primary biliary cirrhosis, Psoriasis, Sjogren'"'"'s syndrome, Vitiligo, gout, celiac disease, atopic dermatitis, acne vulgaris, autoimmune hepatitis, or autoimmune pancreatitis.

19. The method of claim 1, wherein the scaffold comprises 0.1 μ

g to 10 μ

g of said tolerogen.

20. The method of claim 1, wherein the scaffold comprises 0.1 μ

g to 10 μ

g of said recruitment composition.

21. The method of claim 1, wherein said scaffold composition comprises an alginate gel and granulocyte macrophage colony-stimulating factor (GM-CSF).